Codex DNA Unveils Automated Synthetic Biology Solutions for Antibody and Protein Engineering of Biotherapeutic Targets at 18th Annual PEGS Boston Conference and Expo

April 27, 2022

BioXp™ system and RapidAMP™ cell-free DNA kit allow scientists to synthesize, clone, and amplify antibody-variable regions based on a digital sequence input with a single push of a button

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at the PEGS Boston Conference and Expo, which is being held on May 2-6, 2022. The company will be showcasing its proprietary short oligo ligation assembly (SOLA) enzymatic DNA synthesis (EDS) approach and its automated BioXp™ system and RapidAMP™ technology for antibody and protein engineering of biologic drug workflows at booth #425.

"The PEGS Boston conference is recognized as one of the leading international meeting places for the biotherapeutics community," said Todd R. Nelson, PhD, CEO of Codex DNA. "The Codex DNA team is looking forward to meeting with these visionary scientists to discuss how our automated synthetic biology solutions can remove the antibody sequence cloning bottleneck and accelerate therapeutic development."

As biotherapeutic targets become more complex, an increasing number of candidates must be screened in order to identify quality antibody leads against these difficult target classes. To achieve the required level of throughput, scientists have to either rely on long wait times from synthetic biology service providers or labor-intensive manual protocols to build heavy and light chain constructs and amplify them before they are ready for expression.

The combination of Codex DNA's automated BioXp system and RapidAMP technology enables researchers to synthesize lead candidate variable domains, clone them into expression vectors, and amplify the resulting plasmids to transfection scale with the push of a button. The BioXp RapidAMP cell-free DNA amplification kit contains all of the Gibson Assembly® reagents necessary to amplify error-corrected genes cloned into either a made-to-stock or customer vector to make up to 10 micrograms of DNA. The complete platform offers substantial workflow efficiency gains to help bridge the cloning throughput gap that divides lead candidate sequence identification and downstream functional characterization.

FEATURED PRESENTATION
Optimizing production workflows with the BioXp™ system: Overcoming process bottlenecks utilizing automated end-to-end synthetic biology solutions from Codex DNA
Presenter: Jason Lehmann, PhD, Senior Product Marketing Manager, Codex DNA
Date/Time: Friday, May 6, 10:00 am EDT
Location: Room 304

SOLA TECHNOLOGY

Codex DNA scientists will be demonstrating SOLA EDS technology at the PEGS Boston conference. The company's unique SOLA method addresses many of the challenges facing existing EDS approaches related to build length, cost, fidelity, and scalability. Unlike alternative technologies that employ terminal deoxynucleotidyl transferase (TdT), an enzyme that incorporates one DNA base at a time, the streamlined SOLA process generates high-quality synthetic DNA from a universal, pre-manufactured library of short DNA oligos. The short oligos provide the building blocks needed to efficiently assemble complex synthetic genes and mRNA templates using Codex DNA's industry-standard Gibson Assembly method on the automated BioXp system. Together, the SOLA technology and BioXp system have the potential to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins for numerous downstream applications, including biotherapeutics, vaccines, diagnostics, precision medicine, and DNA data storage.

About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding Codex DNA's progress made on achieving corporate goals and the future release of products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond Codex DNA's control, include risks described in Codex DNA's public filings, specifically the section entitled Risk Factors and elsewhere in its annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 23, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Codex DNA disclaims any obligation to update these forward-looking statements.

Media Contact
Richard D. Lepke

Director, Investor Relations
ir@codexdna.com